EUVIMEDEUVIMED entdecken
Crossref

L26/O-311 A comparison of effectiveness for two artificial oocyte activation agents in cycles involving frozen testicular sperm samples

M.S. Uzman, N. Findikli, M. Kaya, Z.U. Gurbuz, T. Sari, A.S. Gurbuz

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von M.S. Uzman und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Is there a difference in the outcome between the use of Calcimycin (A23187) and Ionomycin as AOA agents during TESE-ICSI? Summary answer Compared to Calcimycin (A23187), the utilization of Ionomycin in AOA protocols resulted in significantly higher fertilization and pregnancy rates. What is known already Despite technological advancements, fertilization rates following ICSI remain significantly lower in severe male factor infertility (SMFI) cases. Particularly in TESE-ICSI cycles, oocyte activation failure remains a major barrier to successful fertilization. AOA using calcium ionophores is frequently employed to mimic physiological calcium oscillations and improve outcomes. In clinical practice, two primary agents are utilized for AOA: Calcimycin (A23187) and Ionomycin. While Calcimycin is a conventional ionophore, Ionomycin is distinguished by its superior selectivity in calcium transport and higher activation capacity. Nevertheless, comparative data regarding which agent yields superior clinical outcomes specifically within the TESE-ICSI patient population remain limited. Study design, size, duration Cycles undergoing TESE-ICSI cycles in which AOA was utilized between January 2025, and December 2025 were grouped according to the type of activation agent and retrospectively analyzed in terms of laboratory and clinical outcome. Fertilization rates between the groups were analyzed using the Independent Samples t-test, and pregnancy rates were evaluated using the Pearson chi-square test. Participants/materials, setting, methods A total of 118 SMFI patients undergoing 138 TESE-ICSI cycles were enrolled in the study. Following ICSI, oocytes were incubated in Global Fertilization medium containing either Calcimycin 10 μM (A23187; Catalog No. C7522, Sigma-Aldrich, MO, USA) or 10 μM ionomycin calcium salt (Catalog No. I3909, Sigma-Aldrich, MO, USA) for 10 minutes. The oocytes were then thoroughly washed and moved into Global Total culture media for further incubation until embryo transfer or cryopreservation. Main results and the role of chance Of these 138 cycles, Calcimycin (A23187) was used as the activation agent in 76 cycles, while ionomycin was used in 62 cycles. Patient and cycle demographics, including age, body mass index, infertility duration, total gonadotropin doses, number of oocytes retrieved and, M2 oocytes injected were similar in both groups. Statistical analysis revealed that the ionomycin group achieved a significantly higher mean fertilization rate of 68.70%, compared to 57.16% in the Calcimycin group (p = 0.024). Embryo transfer could not be performed in 15 cycles in the Calcimycin group and 13 cycles in the Ionomycin group due to fertilization failure, cleavage arrest, or social reasons; however, the cycle cancellation rates were similar between the two groups. The bhCG test results showed that ionomycin significantly improved pregnancy success. The bhCG-positive and clinical pregnancy rates per cycle in the ionomycin group were 56.4% (35/62) and 54.8% (34/62), whereas they were 34.2% (26/76) and 28.9% (22/76) in the Calcimycin (A23187) group, respectively. These differences between the two agents were found to be highly significant (p = 0.002). Limitations, reasons for caution The biggest limitations of this study are the number of patients included and its retrospective nature. Future studies with larger datasets are necessary to validate the observed outcomes in this study. Due to the insufficient duration of follow-up, ongoing pregnancy, live birth rates, and neonatal outcomes could not be evaluated. Wider implications of the findings The significant difference in fertilization as well as pregnancy rates demonstrate that the choice of activation agent may have a decisive influence on intracytoplasmic calcium release dynamics of oocytes after ICSI, leading to a better outcome. These findings provide a robust scientific foundation for the standardization of AOA protocols. Trial registration number No

Zitieren

APA

Uzman, M., Findikli, N., Kaya, M., Gurbuz, Z., Sari, T., & Gurbuz, A. (2026). L26/O-311 A comparison of effectiveness for two artificial oocyte activation agents in cycles involving frozen testicular sperm samples. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.309

Vancouver

Uzman M, Findikli N, Kaya M, Gurbuz Z, Sari T, Gurbuz A. L26/O-311 A comparison of effectiveness for two artificial oocyte activation agents in cycles involving frozen testicular sperm samples. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.309

BibTeX
@article{Uzman2026,
  author = {Uzman, M.S. and Findikli, N. and Kaya, M. and Gurbuz, Z.U. and Sari, T. and Gurbuz, A.S.},
  title = {L26/O-311 A comparison of effectiveness for two artificial oocyte activation agents in cycles involving frozen testicular sperm samples},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.309}
}
Kostenlos starten →